Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 20 of the 36 sources its claims cite were checked for support.

Resistance mutations generate divergent antibiotic susceptibility profiles against translation inhibitors

Open access

Abstract

Significance: The ribosome is a large and complex RNA–protein complex that synthesizes proteins in all kingdoms of life. The sequences of bacterial ribosomes differ, and antibiotics exploit these differences to inhibit the ribosome and stop cell growth. Mutations in the ribosome can interfere with antibiotic binding and render the bacteria resistant to the antibiotic. Using a combination of structural, biophysical, and biochemical experiments, we show how rRNA mutations alter the structure of the ribosome at the antibiotic binding site and result in divergent antibiotic susceptibility profiles.

Overview

CoChat Summary

TL;DR

Negamycin-resistant 16S rRNA mutations U1052G and U1060A both reduce negamycin susceptibility, but U1052G unexpectedly becomes hypersusceptible to tetracycline while remaining non-hypersusceptible to tigecycline. Structural and single-molecule experiments link this divergent profile to h34 distortion and a previously unidentified second tetracycline binding site in the U1052G mutant ribosome.

Key findings

  • U1052G and U1060A confer negamycin resistance: MIC values were 256 and 128 µg/mL versus 32 µg/mL for wild-type, with in vitro translation IC50 values of 13 and 11 µM versus 2.9 µM for wild-type.
  • U1052G is hypersusceptible to tetracycline: MIC 0.5 µg/mL versus 2 µg/mL for wild-type, and in vitro translation IC50 2.7 µM versus 15 µM for wild-type; U1060A was tetracycline-resistant (MIC 16 µg/mL; IC50 51 µM).
  • X-ray crystallography showed U1052G disrupts the U1052–G1206 wobble pair and displaces the G1053 phosphate by ∼2 Å, while also revealing a second tetracycline molecule bound ∼20 Å from the established site near the 16S central pseudoknot and ribosomal protein S5; no second site was found in wild-type or U1060A ribosomes.
  • U1052G showed no hypersusceptibility to tigecycline (MIC 2 µg/mL; IC50 0.36 µM versus wild-type MIC 2 µg/mL and IC50 0.28 µM), and modeling suggested the tigecycline butylglycylamido substituent would clash with S5 at the novel site.

Methods

  • The study used microbiological MIC measurements, luminescence-based in vitro-coupled transcription–translation assays with purified components, X-ray crystallography of E. coli strain SQ171 70S ribosomes, and single-molecule FRET (smFRET) to monitor aa-tRNA selection.
  • Ribosomes were wild-type or carrying U1052G or U1060A mutations; antibiotic complexes included negamycin, tetracycline, and tigecycline, with structures deposited under PDB IDs 5IT8, 5J5B, 5J91, 5JC9, 5J7L, 5J8A, and 5J88.
  • Crystallographic data were processed with XDS/SCALA/autoPROC, solved by molecular replacement with MOLREP, rebuilt in Coot, and refined with autoBUSTER; smFRET experiments tracked Cy3-labeled initiator tRNA and LD650-labeled Phe-tRNAPhe in ternary complex with EF-Tu and GTP.

Limitations

  • The paper states that attempts to introduce G966U or G1058C tetracycline-resistance mutations together with U1052G failed to produce viable clones, and a randomized library at positions 965–967 yielded tetracycline-resistant isolates only with wild-type U1052, preventing direct mutagenic testing of the novel binding site’s function.
  • The paper states that future work is needed to determine whether other antibiotic resistance mutations in pathogens create novel antibiotic binding sites that can be exploited therapeutically.
  • Evident from the text: the causal role of the second tetracycline binding site in U1052G hypersusceptibility is supported by correlation with structural and smFRET data, but the attempted functional disruption of that site was not achieved.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1073/pnas.1605127113

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

9 Valid · 3 Not valid · 11 Not checked · 54 Own results and interpretations

41 more claims · 5 with their cited sources checked

Create a free account to see all 77 claims and to verify the 16 references still open.

See all claims — free account
  • It may state two separate claims as one. 22
  • Probably not a substantial claim. 14
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 37 references

Research works printed but not linked: 2

  1. G Bricogne, Buster Version V2.11.6 (Global Phasing Ltd., Cambridge, UK, 2011).
  2. OS Smart, Grade V. 1.2.9 (Global Phasing Ltd., Cambridge, UK, 2011).

Cited by

See all 56

Metadata

Authors
Cocozaki, A. I., Altman, R. B., Huang, J., Buurman, E. T., Kazmirski, S. L., Doig, P., Prince, D. B., Blanchard, S. C., Cate, J. H. D., & Ferguson, A. D.
Affiliations
  • AstraZeneca (United States) (US)
  • Tri-Institutional PhD Program in Chemical Biology (US)
  • University of California, Berkeley (US)
Venue
Proceedings of the National Academy of Sciences
Published
2016-07-05
Volume
113
Issue
29
Pages
8188-8193
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2462749337
Cited by
56
References
37
Citations by year
2026: 6 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 3 · 2021: 4 · 2020: 9 · 2019: 2 · 2018: 9 · 2017: 1
FWCI
2.08
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
Funders
  • AstraZeneca
  • National Institute of General Medical Sciences (R01GM079238, R01GM098859)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
Keywords
antibiotic resistance, translation inhibitors, negamycin, tetracycline, 16S rRNA, 30S ribosomal subunit, tRNA binding, ribosome structure, Escherichia coli
MeSH terms
Amino Acids, Diamino, Anti-Bacterial Agents, Escherichia coli, Mutation, Protein Synthesis Inhibitors, Ribosomes, RNA, Bacterial, RNA, Ribosomal, Tetracycline, Drug Resistance, Bacterial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resistance mutations generate divergent antibiotic susceptibility profiles against translation inhibitors. https://app.cochat.ai/papers/10.1073/pnas.1605127113
The paper
Cocozaki, A. I., Altman, R. B., Huang, J., Buurman, E. T., Kazmirski, S. L., Doig, P., Prince, D. B., Blanchard, S. C., Cate, J. H. D., & Ferguson, A. D. (2016). Resistance mutations generate divergent antibiotic susceptibility profiles against translation inhibitors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1605127113

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.